Latest Security News

Lynas Rare Earths reported FY25 results featuring record NdPr output and the first commercial heavy rare earths production outside China, alongside a $750 million equity raise to fund its ambitious Towards 2030 growth strategy.

Dimerix Limited reported a 22% reduction in its FY2025 loss to $13.25 million, driven by strong licensing revenues and advancing its pivotal Phase 3 clinical trial for DMX-200. The company secured new global partnerships valued at up to AU$1.4 billion, bolstering its cash reserves and commercial prospects.

Beamtree Holdings delivered a standout Q4 FY25 with a 12% jump in annual recurring revenue and a 48% surge in operating profit, setting a strong foundation for FY26 growth despite upcoming CFO transition.

Perpetual Limited has announced an ordinary unfranked dividend of AUD 0.54 per share for the half-year ending June 2025, accompanied by a Dividend Reinvestment Plan offering shareholders a choice to reinvest without discount.

Perpetual Limited reported a modest 2% revenue increase for FY25, yet its net profit after tax plunged by 88%, prompting a cautious outlook despite a declared final dividend.

Emyria Limited reports a reduced net loss of $3.14 million for FY2025, driven by strategic expansion in psychedelic-assisted mental health treatments and key partnerships including insurer Medibank. The company advances clinical services while continuing R&D on proprietary medicines.

DroneShield was not selected as the Systems Integration Partner for the Australian Defence’s LAND 156 program, yet it reported record half-year revenue and profit driven by strong global demand for its counterdrone technology.

Biome Australia has secured key distribution partnerships with Mecca and Go Vita, launching its Activated Probiotics range into premium beauty and health food channels across Australia.

Micro-X reported FY25 revenue of $13.1 million, underpinned by significant US government contracts and pioneering 3D head CT imaging technology, setting the stage for clinical trials and commercial expansion.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.

AnteoTech Ltd reports a strong FY2025 with doubled sales revenue, strategic partnerships, and key product milestones in battery materials and life sciences diagnostics.

Micro-X Limited reported a $13.9 million loss for FY2025 as it pivots towards medical imaging, securing a landmark supply agreement with a major US healthcare provider for its Rover Plus mobile X-ray system.